Biodexa Pharmaceuticals Plc Gross Profit

The latest gross profit for BDRX is $-5M as of June 2026. That compares with $-4.4M in the prior-year period — down 15.7% year over year. That is below the Healthcare sector average of $66B. Investors often review this figure alongside Biodexa Pharmaceuticals Plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, BDRX's gross profit moved from $-4.4M to $-5M — a 15.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Biodexa Pharmaceuticals Plc's operating scale or balance-sheet position.

Against Healthcare companies, BDRX currently prints $-5M for gross profit, while the sector average sits near $66B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Biodexa Pharmaceuticals Plc's growth, margins, and balance sheet.

A gross profit figure of $-5M for BDRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $66B. Explore the charts below for those layers of context.

After noting BDRX's gross profit ($-5M), review year-over-year change from $-4.4M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.